GlassScriptPhysician profile
Shivana Tate
NPI 1487122206
$3,562.97
in general payments reported to CMS, 2019-2025
25 companies · $75.18 in 2025
The $75.18 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,261 · 2022: $1,851 · 2023: $320 · 2024: $56.18 · 2025: $75.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $797.35 | 2021-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $516.87 | 2021-2023 | Farxiga, Breztri |
| Abbvie INC. | $474.49 | 2021-2023 | |
| Amgen INC. | $304.35 | 2021-2023 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $215.06 | 2022-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $163.44 | 2022 | |
| Glaxosmithkline, LLC. | $143.11 | 2021-2022 | |
| Astellas Pharma US INC | $125.24 | 2022-2023 | Myrbetriq |
| Amarin Pharma, INC. | $118.92 | 2021 | |
| Merck Sharp & Dohme LLC | $103.88 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.49 | 2021-2022 | |
| Eisai INC. | $76.93 | 2021 | |
| Pfizer INC. | $67.07 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.44 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $55.54 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $48.15 | 2021 | |
| Exact Sciences Corporation | $45.93 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $37.25 | 2022 | |
| Medtronic, INC. | $28.93 | 2024 | Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $15.65 | 2021 | |
| Sumitomo Pharma America, INC. | $15.51 | 2025 | Gemtesa |
| Biogen, INC. | $14.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.99 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.69 | 2021 | |
| Ibsa Pharma INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivana Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.